News

Eli Lilly: 50% Upside For LLY Stock?
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly drops as trial data for oral obesity drug weigh on Q2 results
(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why.
Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...
Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...